免疫療法中のCD8T幹細胞のコントロール
Tae Gun Kang1, Xin Lan1,2, Tian Mi1
1Department of Immunology, St. Jude Children's Research Hospital, Memphis, TN 38105, USA.
まとめ
ASXL1のようなエピジェネティックレギュレータは,がん免疫療法におけるT細胞枯渇に不可欠です. これらのエピジェネティック要因を調節することで,抗腫瘍免疫が強化され,患者の生存率も向上します.
科学分野:
- 免疫学
- エピジェネティクス
- 癌 研究
背景:
- T細胞の枯渇は,がん免疫療法における重要な障害であり,T細胞の反応の有効性を制限する.
- 慢性的な抗原曝露と抗腫瘍免疫の間にT細胞の枯渇を制御する特定の表遺伝子調節体は,まだ完全に理解されていません.
研究 の 目的:
- T細胞幹細胞とチェックポイント阻害免疫療法の反応における3つの一般的に変異した表遺伝子調節体の役割を調査する.
- これらのレギュレータがT細胞機能と抗腫瘍免疫に影響を与えるメカニズムを解明する.
主な方法:
- 慢性抗原被曝中にDnmt3a,Tet2,またはAsxl1が欠けているCD8T細胞の分析
- H2AK119のユビキチン化と表遺伝子経路によるT細胞の自己再生と分化におけるAsxl1の役割の調査.
- Asxl1欠乏性T細胞と抗PD-L1免疫療法の併用による実験モデルでの評価
主要な成果:
- Dnmt3a,Tet2,またはAsxl1に欠けているCD8T細胞は,悪性変異なしに1年以上前駆体 (Tpex) 集団を維持した.
- Asxl1欠乏症はT細胞の自己再生能力を維持し,CD8 T細胞の分化を減少させた.
- Asxl1欠乏性T細胞は,抗PD- L1免疫療法と相乗効果を示し,臨床前モデルでは腫瘍制御の改善と生存の向上をもたらした.
結論:
- Asxl1は,特定の表遺伝的メカニズムを通じて,T細胞の枯渇と抗腫瘍免疫を調節する上で重要な役割を果たします.
- Asxl1のようなエピジェネティック・レギュレータをターゲットにすることで 癌の免疫療法の効果が向上する見込みです
- Asxl1欠乏性T細胞は,がん治療における患者の成果を改善するための貴重な治療戦略を代表する可能性があります.
関連する概念動画
Regulation of Hematopoietic Stem Cells
3.2K
All blood and immune cells are produced from the multipotent hematopoietic stem cells (HSCs) by the process of hematopoiesis. However, they all have a limited life span. In addition, many are depleted in immune surveillance or combatting an injury or infection. This makes blood one of the most regenerative tissues. Hematopoiesis helps replenish these blood and immune cells, restoring the body's normal functioning. However, overproduction of blood and immune cells can make them cancerous or...
3.2K
Multipotency of Hematopoietic Stem Cells
3.0K
The hematopoietic stem cells or HSCs are multipotent, meaning they can differentiate and give rise to all blood and immune cells. HSCs are maintained in the quiescent stage until an external stimulus initiates their differentiation. The multipotent HSCs exist as two heterogeneous populations, long-term repopulating cells (LTRC) and short-term repopulating cells (STRC). The two HSC populations have different surface markers or receptors and are classified based on quiescence and long-term...
3.0K
Lineage Commitment
3.0K
Commitment is the process whereby stem cells:
3.0K
T Cell Activation and Clonal Selection
679
T cells are integral to our adaptive immune system, recognizing and effectively responding to foreign antigens. T cell activation and clonal selection are pivotal in orchestrating this immune response. This article elucidates these mechanisms, detailing the roles of cluster of differentiation (CD) markers, major histocompatibility complex (MHC) molecules, costimulatory signals, and the process of clonal selection.
Naive T cells that have not yet encountered an antigen express two primary CD...
Naive T cells that have not yet encountered an antigen express two primary CD...
679
Role of Hematopoietic Growth Factors
1.3K
Hematopoietic growth factors are molecules that regulate the differentiation rate of hematopoietic stem cells (HSCs). Erythropoietin (EPO), primarily produced by the kidneys, plays a crucial role in erythrocyte production. When oxygen levels in the blood are low, EPO is released into the bloodstream, reaching the bone marrow, where it stimulates HSCs to differentiate and mature into erythrocytes, which are vital for oxygen transport.
Thrombopoietin (TPO), mainly released by the liver,...
Thrombopoietin (TPO), mainly released by the liver,...
1.3K
Cancer Stem Cells and Tumor Maintenance
4.9K
Early diagnosis and treatment can often cure cancer. However, even with treatment, residual cells called cancer stem cells (CSC) might remain, often causing tumor recurrence. These cancer stem cells possess the potential for self-renewal and multi-lineage differentiation and are often responsible for the therapeutic resistance displayed in most cancers.
Cancer stem cells are thought to originate from tissue-specific normal stem cells or progenitor cells. The normal stem cells usually reside in...
Cancer stem cells are thought to originate from tissue-specific normal stem cells or progenitor cells. The normal stem cells usually reside in...
4.9K


